Omeprazole, lansoprazole and pantoprazole are metabolized by several human cytochromes P450, most prominently by CYP2C19 and CYP3A4. Only pantoprazole is also metabolized by a sulfotransferase. Differences in the quantitative contribution of these enzymes and in the relative affinities of the substrates explain some of the observed interactions with carbamazepin, diazepam, phenytoin and theophylline and of the impact of the CYP2C19 (mephenytoin) genetic polymorphism. Of these drugs, pantoprazole has the lowest potential for interactions, both in vitro and in human volunteer studies.
INTRODUCTION
The proton pump inhibitors (PPIs)b omeprazole, pantoprazole and lansoprazole are substituted benzimidazole sulfoxides with similar dose-efficacy profiles. Elimination of these drugs occurs almost entirely by rapid metabolism to inactive or less active metabolites, so that virtually no unchanged drug is excreted in urine and feces. The clearances of PPIs are between 0.1 and 0.5 1/h/kg-body-weight and the plasma half-lives range from 0.3 to 2.2 hr [1] [2] [3] [4] . Drug metabolism is subject to genetic and environmental variation, which is a frequent cause of patient-to-patient differences in drug effects. The differences in the metabolism of these drugs, therefore, may favorably or unfavorably affect the potential for interactions, enzyme induction and genetically polymorphic metabolism. On the other hand, it is well known that the inhibitory effect of these drugs on acid secretion persists for a long time, in spite of their rapid elimination.
METABOLISM OF OMEPRAZOLE, LANSOPRAZOLE AND PANTOPRAZOLE Omeprazole
Omeprazole remains the most extensively studied of the PPIs in regard to its metabolism ( Figure 1 ) [5, 6] . Omeprazole is primarily metabolized by aliphatic hydroxylation of the pyridinyl methyl group to hydroxy-omeprazole and by oxidation of the sulfoxide group to form omeprazole sulfone. Both metabolites are further metabolized to the hydroxysulfone. In vitro studies in human liver mircrosomes have also revealed some participation of CYP2C19, CYP3A and CYP2D6 in the formation of secondary and minor metabolites [6] . Two well-known cytochromes P450, CYP2C19 (S-mephenytoin hydroxylase) and CYP3A4 (nifedipine oxidase), catalyze these reactions. CYP2C19 exhibits a significant genetic polymorphism, and poor metabolizers of S-mephenytoin are also poor metabolizers of omeprazole [7] [8] [9] [10] 
Lansoprazole
The major metabolic pathway of lansoprazole involves the formation of lansoprazole sulfone from the sulfoxide group ( Figure 2 ). Lansoprazole sulfone is also the main metabolite present in serum. Hydroxylansoprazole is also formed, but the hydroxylation occurs at a different position (carbon 5 of the benzimidazole moiety) than for omeprazol (5-methyl carbon of the pyridinyl group). Studies with human liver microsomes and human hepatocytes in culture [1] indicate that, as with omeprazole, CYP3A4 is the major enzyme involved in the sulfone formation. However, the enzymes catalyzing the hydroxylation are less clearly identified and contributions of the cytochromes CYP3A4, CYP2C 18, CYP2C19 and others are suspected [ 1] . Pantoprazole Pantoprazole (Figure 3 ) is also completely metabolized in the liver. It undergoes 0-demethylation by CYP2C19, which is followed by sulfate conjugation and some sulfone or sulfide formation, either by oxidation or reduction of the sulfoxide group [3, 4] . Recent in vivo and in vitro studies in human liver microsomes suggest that in addition to a cytosolic sulfotransferase, CYP2C19 and CYP3A4 affect the clearance of pantoprazole, i.e., poor metabolizers of pantoprazole were also poor metabolizers of mephenytoin ( [8] . **Data from Byk Gulden, Konstanz, Germany. tNumber of volunteers.
human liver [21] and gut [22] . This effect has also been demonstrated in vivo in human volunteers by increased N3-demethylation of caffeine after omeprazole administration [24, 25] or increased clearance of theophylline after lansoprazole treatment [26] . In human hepatocyte cultures [27] , CYP3A4 also was induced by omeprazole and its sulfone, and by lansoprazole. The induction effect is concentration-dependent and, thus, occurs at lower doses in poor metabolizers of mephenytoin. The molecular mechanism of the induction of CYPIA1/2 and CYP3A4 by these drugs is not exactly known [28, 29] [32, 33] , and this inhibition is more apparent in individuals of the mephenytoin extensive metabolizer phenotype (EMs), indicating that at therapeutic concentrations omeprazole and diazepam compete for the same site on CYP2C19. Neither lansoprazole [34] nor pantoprazole [35] seem to affect diazepam kinetics. A decrease in the clearance of phenytoin [36] and carbamazepin [37] points to interaction of omeprazole with other cytochromes P450, presumably of the CYP2C9 subfamily. Lansoprazole and pantoprazole apparently do not interact with CYP2C19 and other CYP2C substrates. The induction of CYP1A2 by omeprazole and lansoprazole is reflected by the increased clearance of caffeine [24, 25] and theophylline [26] , respectively. No clinically relevant interactions of the three drugs with most CYP3A4 substrates have been observed. Extensive studies with pantoprazole showed this drug to have the lowest potential of these three drugs for metabolic interactions in vitro and in vivo. The present data-base on interactions is summarized in Table 2 and References 1-4, 30, and 38.
